CYTOAGENTS INC

From the company

& Events Media Coverage Press Releases Events Contact Innovative Treatment for a Pipeline of Inflammatory Indications Cyto Agents is advancing CTO1681 for multiple indications where dysregulated cytokine signaling plays a central role in disease pathogenesis. Therapeutic indications include pulmonary arterial hypertension (PAH), asthma, atopic dermatitis (AD), and inflammation within the tumor microenvironment. Our Vision Immune hyperactivation and dysregulation are key drivers of disease pathogenesis and complications across oncology and inflammatory diseases, specifically in the tumor microenvironment, as well as in asthma, COPD, and atopic dermatitis. Hyperactivation of the immune system limits efficacy of cell therapies and causes life threatening treatment-related toxicities. Greater than 60% of acute exacerbations in asthma and COPD are driven by viral infections that further.